UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study

International journal of clinical practice (Esher), 2007-10, Vol.61 (10), p.1671-1676

2007

Volltextzugriff (PDF)

Conversion from Standard Opioid Therapy to Once-daily Oral Extended-release Hydromorphone in Patients with Chronic Cancer Pain

Journal of international medical research, 2008-03, Vol.36 (2), p.343-352

2008

Volltextzugriff (PDF)

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Annals of oncology, 2018-10, Vol.29, p.viii97-viii97

2018

Volltextzugriff (PDF)

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

Annals of oncology, 2018-10, Vol.29, p.viii97-viii97

2018

Volltextzugriff (PDF)

A multicenter risk index for atrial fibrillation after cardiac surgery

JAMA : the journal of the American Medical Association, 2004-04, Vol.291 (14), p.1720

2004

Volltextzugriff (PDF)

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Annals of oncology, 2018-10, Vol.29, p.viii96-viii97

2018

Volltextzugriff (PDF)

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Annals of oncology, 2018-10, Vol.29, p.viii96-viii96

2018

Volltextzugriff (PDF)

162PHospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

305PExposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

Annals of oncology, 2019-05, Vol.30, p.iii52-iii52

2019

Volltextzugriff (PDF)

The Risk Associated with Aprotinin in Cardiac Surgery

The New England journal of medicine, 2006-01, Vol.354 (4), p.353-365

2006

Volltextzugriff (PDF)

306PExposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

304PEMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

303PEMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

Annals of oncology, 2015-05, Vol.26, p.iii6-iii6

2015

Volltextzugriff (PDF)

Flexible Decision Support System for Algorithmic Trading: Empirical Application on Crude Oil Markets

IEEE access, 2022, Vol.10, p.9628-9644

2022

Volltextzugriff (PDF)

Abstract OT3-03-02: A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-03-02-OT3-03-02

2019

Volltextzugriff (PDF)

Impact of hyperglycemia on perioperative mortality after coronary artery bypass graft surgery

The Journal of thoracic and cardiovascular surgery, 2011-08, Vol.142 (2), p.430-437.e1

2011

Volltextzugriff (PDF)

Abstract P6-18-12: EMBRACA: Efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: A regional analysis

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-12

2019

Volltextzugriff (PDF)

Aspirin and Mortality from Coronary Bypass Surgery

The New England journal of medicine, 2002-10, Vol.347 (17), p.1309-1317

Mangano, Dennis T

2002

Volltextzugriff (PDF)

Abstract P2-07-04: A novel diagnostic androgen receptor gene signature links clinical outcomes and preclinical response to enzalutamide, paclitaxel or the combination in triple-negative breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-07-04

2016

Volltextzugriff (PDF)

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS4-07-GS4-07

2018

Volltextzugriff (PDF)

Abstract OT3-02-02: ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT3-02-02-OT3-02-02

2017

Volltextzugriff (PDF)

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS6-07-GS6-07

2018

Volltextzugriff (PDF)

Thy1 transgenic mice expressing the red fluorescent calcium indicator jRGECO1a for neuronal population imaging in vivo

PloS one, 2018-10, Vol.13 (10), p.e0205444-e0205444

2018

Volltextzugriff (PDF)

1 – 25 von 2.385

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.031)
Mit Volltextzugriff
(1.935)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.542)
Life Sciences & Biomedicine
(1.129)
Humans
(867)
Female
(578)
Male
(568)
Middle Aged
(308)
Aged
(290)
Animals
(266)
Adult
(265)
Biological And Medical Sciences
(243)
Physical Sciences
(212)
Technology
(198)
Medical Sciences
(184)
Neurosciences & Neurology
(174)
Treatment Outcome
(157)
Aged, 80 And Over
(132)
Science & Technology - Other Topics
(131)
Adolescent
(129)
Exercise
(128)
Cardiovascular System & Cardiology
(125)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study

Conversion from Standard Opioid Therapy to Once-daily Oral Extended-release Hydromorphone in Patients with Chronic Cancer Pain

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

A multicenter risk index for atrial fibrillation after cardiac surgery

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

162PHospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

305PExposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

The Risk Associated with Aprotinin in Cardiac Surgery

306PExposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

304PEMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

303PEMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

Flexible Decision Support System for Algorithmic Trading: Empirical Application on Crude Oil Markets

Abstract OT3-03-02: A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)

Impact of hyperglycemia on perioperative mortality after coronary artery bypass graft surgery

Abstract P6-18-12: EMBRACA: Efficacy and safety of talazoparib or physician's choice of therapy in patients with advanced breast cancer and a germline BRCA1/2 mutation: A regional analysis

Aspirin and Mortality from Coronary Bypass Surgery

Abstract P2-07-04: A novel diagnostic androgen receptor gene signature links clinical outcomes and preclinical response to enzalutamide, paclitaxel or the combination in triple-negative breast cancer

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

Abstract OT3-02-02: ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

Thy1 transgenic mice expressing the red fluorescent calcium indicator jRGECO1a for neuronal population imaging in vivo

Suchergebnisse filtern